Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
Drug Eruption and Interactions - PHARMACEUTICAL REVIEW Drug Eruption and Interactions - PHARMACEUTICAL REVIEW
(1989): Kerker BJ+, Semin Dermatol 8, 173 (1987): Katsanis E+, Am J Pediatr Hematol Oncol 9, 204 (1984): Flynn TC+, JAmAcadDermatol11, 584 Petechiae (1998): Taverna C+, Schweiz Med Wochenschr (German) 128, 1117 Photo-recall (2006): Kaya TI+, J Eur Acad Dermatol Venereol 20(3), 353 Pruritus (1–10%) Rash (sic) (>10%) (2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481 (40–73%) Seborrheic keratoses (inflammation of) (Leser–Trélat syndrome) (1999): Williams JV+, JAmAcadDermatol40, 643 Squamous syringometaplasia (1990): Bhawan J+, Am J Dermatopathol 12, 1 Toxic epidermal necrolysis (2001): Özkan A+, Pediatr Dermatol 18(1), 38 (1998): Figueiredo MS+, Rev Assoc Med Bras (Portuguese) 44, 53 Ulcerations Urticaria (2002): Cetkovska P+, J Eur Acad Dermatol Venereol 16(5), 481 Vasculitis* (1998): Ahmed I+, Mayo Clin Proc 73, 239 (1989): Kerker BJ+, Semin Dermatol 8, 173 (1989): Williams SF+, Br J Haematol 73, 274 Mucosal Oral lesions (1986): Morant R+, Schweiz Med Wochenschr (German) 116, 1415 (1–5%) Oral ulceration (>10%) Perianal ulcerations (>10%) Stomatitis (1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim) Hair Hair – alopecia (1–10%) (1988): Benson PM+, J Assoc Military Derm XIV, 28 (passim) (1986): Morant R+, Schweiz Med Wochenschr (German) 116, 1415 (100%) Nails Nails – leukonychia (1990): Bader-Meunier B+, Ann Pediatr Paris (French) 37, 337 Nails – Mees’ lines (1982): Jeanmougin M+, Ann Dermatol Venereol (French) 109, 169 Eyes Conjunctivitis (2006): Matteucci P+, Haematologica 91(2), 255 Other Anaphylactoid reactions/Anaphylaxis (1997): Blanca M+, Allergy 52, 1009 (1989): Williams SF+, Br J Haematol 73, 274 (1980): Rassiga AL+, Arch Intern Med 104, 425 Hypersensitivity (1992): Weiss RB, Semin Oncol 19, 458 Infections (1997): Whitlock JA+, Leukemia 11(2), 185 (39%) (with etopside) Injection-site cellulitis (1–10%) Myalgia/Myositis/Myopathy/Myotoxicity (1–10%) Neurotoxicity (2006): Nakajima D+, No To Hattatsu 38(3), 195 (2006): Saito T+, J Infect Chemother 12(3), 148 Rhabdomyolysis (2002): Truica CI+, Am J Hematol 70(4), 320 (1997): Morales-Polanco M+, Arch Med Res 28(3), 377 (5 cases) (1987): Margolis D+, Cancer Treat Rep 71(12), 1325 Thrombophlebitis (>10%) *Note: Vasculitis, a part of the cytarabine syndrome, consists of fever, malaise, myalgia, conjunctivitis, arthralgia and a diffuse erythematous maculopapular eruption that occurs from 6 to 12 hours following the administration of the drug DACARBAZINE Synonym: DIC Trade names: D.T.I.C; Dacatic; Deticene; Detimedac; DTIC- Dome (Bayer) Indications: Malignant melanoma, carcinomas Category: Alkylating agent; Antineoplastic Half-life: initial: 20–40 minutes Clinically important, potentially hazardous interactions with: aldesleukin Reactions DACARBAZINE 159 Skin Actinic keratoses (1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192 Angioedema (1981): Wassilew SW+, Hautarzt (German) 32 (Suppl 5), 453 Erythema Exanthems (1981): Wassilew SW+, Hautarzt (German) 32 (Suppl 5), 453 Fixed eruption (1982): Koehn GG+, Arch Dermatol 118, 1018 Photosensitivity (
160 DACARBAZINE (2001): Ramanathan RK+, Ann Oncol 12(8), 1139 Fever (2004): Buesa JM+, Cancer 101(10), 2261 (with gemcitabine) Hypersensitivity (2006): Levy A+, Ann Dermatol Venereol 133(2), 157 (20%) (1992): Weiss RB, Semin Oncol 19, 458 Injection-site burning (>10%) Injection-site cellulitis (1989): Kerker BJ+, Semin Dermatol 8, 173 Injection-site dermatitis (1987): Dufresne RG, Cutis 39, 197 Injection-site necrosis (>10%) (1987): Dufresne RG, Cutis 39, 197 Injection-site pain (>10%) Injection-site phlebitis (1989): Kerker BJ+, Semin Dermatol 8, 173 Myalgia/Myositis/Myopathy/Myotoxicity (1–10%) Rhabdomyolysis (1995): Anderlini P+, Cancer 76(4), 678 DACLIZUMAB Trade name: Zenapax (Roche) Indications: Transplant rejection Category: Immunosupressant; Monoclonal antibody Half-life: N/A Clinically important, potentially hazardous interactions with: corticosteroids, cyclosporine, hemophilus B vaccine, methylprednisolone, mycophenolate, prednisolone Reactions Other Application-site reactions Hypersensitivity Infections (2004): Huang XS+, Di Yi Jun Yi Da Xue Xue Bao 24(2), 126 DACTINOMYCIN Synonyms: ACT; actinomycin D Trade names: Ac-De; Cosmegen (Merck); Cosmegen Lyovac; Lyovac Indications: Melanomas, sarcomas Category: Antibiotic, anthracycline Half-life: 36 hours Clinically important, potentially hazardous interactions with: aldesleukin Reactions Skin Acne (>10%) (1993): Blatt J+, Med Pediatr Oncol 21, 373 (1983): Bronner AK+, JAmAcadDermatol9, 645 (1982): Dunagin WG, Semin Oncol 9, 14 Actinic keratoses (1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192 Bullous pemphigoid (1982): Amer MH+, Int J Dermatol 21, 32 Cellulitis (1989): Kerker BJ+, Semin Dermatol 8, 173 Dermatitis Erythema (1997): Coppes MJ+, Med Pediatr Oncol 29, 226 Erythema multiforme Exanthems Folliculitis (1981): Henkes J+, Actas Dermosifiliogr (Spanish) 72, 469 Keratoses (reactivation of) (1989): Kerker BJ+, Semin Dermatol 8, 173 Lichenoid eruption (2006): Ridola V+, Pediatr Dermatol 23(5), 503 Photo-recall (>10%) (1997): Coppes MJ+, Med Pediatr Oncol 29, 226 Pigmentation (2000): Marcoux D+, JAmAcadDermatol43, 540 (with vincristine) (1995): Kanwar VS+, Med Pediatr Oncol 24, 329 Pruritus (2006): Ridola V+, Pediatr Dermatol 23(5), 503 (1989): Kerker BJ+, Semin Dermatol 8, 173 Pustules (1983): Bronner AK+, JAmAcadDermatol9, 645 Toxic epidermal necrolysis Urticaria Mucosal Cheilitis Oral lesions (1983): Bronner AK+, JAmAcadDermatol9, 645 (>5%) Stomatitis (ulcerative) (>5%) Hair Hair – alopecia (>10%) Other Anaphylactoid reactions/Anaphylaxis (10%) (1997): Coppes MJ+, Med Pediatr Oncol 29, 226 Injection-site necrosis (>10%) (1987): Dufresne RG, Cutis 39, 197 Injection-site phlebitis (>10%) Myalgia/Myositis/Myopathy/Myotoxicity Phlebitis (1989): Kerker BJ+, Semin Dermatol 8, 173 DALTEPARIN Trade names: Fragmin (Pfizer); Fragmine Indications: Prophylaxis of deep vein thrombosis Category: Heparin, low molecular weight Half-life: 4–8 hours Clinically important, potentially hazardous interactions with: butabarbital, danaparoid Reactions Skin Allergic reactions (sic) (1–10%) (2003): Myers B+, Blood Coagul Fibrinolysis 14(5), 485 (1999): Ensom MH+, Pharmacotherapy 19(9), 1013 (1993): Phillips JK+, Br J Haematol 84(2), 349 Bullous dermatitis (1–10%) (1999): Tong, M, Kota Kinabalu, Malaysia (from Internet) (observation) Exanthems (
- Page 184 and 185: Herpes zoster (
- Page 186 and 187: Hypersensitivity Injection-site pai
- Page 188 and 189: Other Abdominal pain (25%) Anaphyla
- Page 190 and 191: CHLORAMBUCIL Trade names: Chloramin
- Page 192 and 193: (1992): Ramselaar CG+, Br J Urol 70
- Page 194 and 195: (1997): Selvaag E, Ann Trop Pediatr
- Page 196 and 197: (1989): Rosen C, Semin Dermatol 8,
- Page 198 and 199: CHOLESTYRAMINE Trade names: Chol-Le
- Page 200 and 201: CIMETIDINE Trade names: Apo-Cimetid
- Page 202 and 203: (2000): Sharobeem KM+, J Cardiovasc
- Page 204 and 205: (1997): Carrasco JM+, Ann Pharmacot
- Page 206 and 207: CITALOPRAM Synonym: nitalapram Trad
- Page 208 and 209: CLEMASTINE Trade names: Aller-Eze;
- Page 210 and 211: Other Hypersensitivity (2002): Somm
- Page 212 and 213: CLOMIPRAMINE Trade names: Anafranil
- Page 214 and 215: CLOPIDOGREL Trade name: Plavix (Bri
- Page 216 and 217: Eczema (
- Page 218 and 219: (1997): Thaler D, Monona, WI (from
- Page 220 and 221: COCOA Scientific names: Theobroma c
- Page 222 and 223: COLESEVELAM Trade name: Welchol (Sa
- Page 224 and 225: CORDYCEPS Scientific name: Cordycep
- Page 226 and 227: CYCLAMATE Trade name: Sucaryl (Abbo
- Page 228 and 229: Inappropriate secretion of antidiur
- Page 230 and 231: (1996): Cox NH, Clin Exp Dermatol 2
- Page 232 and 233: (2007): Lim AK+, Intern Med J 37(1)
- Page 236 and 237: Pruritus (1-10%) Rash (sic) (1-10%)
- Page 238 and 239: (1988): Tham SN+, Singapore Med J 2
- Page 240 and 241: DASATINIB Synonym: BMS354825 Trade
- Page 242 and 243: Other Anaphylactoid reactions/Anaph
- Page 244 and 245: (1980): Miescher PA+, Clin Haematol
- Page 246 and 247: (1985): Job JC+, Arch Fr Pediatr 42
- Page 248 and 249: DEXTROMETHORPHAN Trade names: Balmi
- Page 250 and 251: Erythema nodosum (
- Page 252 and 253: Mucosal Oral ulceration Hair Hair -
- Page 254 and 255: (1987): Masden JJ+, Curr Ther Res 4
- Page 256 and 257: (1998): Knowles S+, JAmAcadDermatol
- Page 258 and 259: Epiphora Other Abdominal pain Fever
- Page 260 and 261: DISOPYRAMIDE Trade names: Dimodan;
- Page 262 and 263: (1995): Cortes JE+, J Clin Oncol 13
- Page 264 and 265: DOMPERIDONE Trade names: Evoxin; Mo
- Page 266 and 267: DOXAPRAM Trade name: Dopram (Baxter
- Page 268 and 269: (1989): Jones AP+, Br J Cancer 59,
- Page 270 and 271: (1992): Bennett MJ, JRArmyMedCorps1
- Page 272 and 273: ECHINACEA Scientific names: Echinac
- Page 274 and 275: Hot flashes (
- Page 276 and 277: Pemphigus vegetans (1994): Bastiaen
- Page 278 and 279: Stevens-Johnson syndrome (
- Page 280 and 281: Ocular pruritus (1-10%) Other Cough
- Page 282 and 283: (2002): Bohm M+, Drug Saf 25(8), 59
160 DACARBAZINE<br />
(2001): Ramanathan RK+, Ann Oncol 12(8), 1139<br />
Fever<br />
(2004): Buesa JM+, Cancer 101(10), 2261 (with gemcitabine)<br />
Hypersensitivity<br />
(2006): Levy A+, Ann Dermatol Venereol 133(2), 157 (20%)<br />
(1992): Weiss RB, Semin Oncol 19, 458<br />
Injection-site burning (>10%)<br />
Injection-site cellulitis<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
Injection-site dermatitis<br />
(1987): Dufresne RG, Cutis 39, 197<br />
Injection-site necrosis (>10%)<br />
(1987): Dufresne RG, Cutis 39, 197<br />
Injection-site pain (>10%)<br />
Injection-site phlebitis<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
Myalgia/Myositis/Myopathy/Myotoxicity (1–10%)<br />
Rhabdomyolysis<br />
(1995): Anderlini P+, Cancer 76(4), 678<br />
DACLIZUMAB<br />
Trade name: Zenapax (Roche)<br />
Indications: Transplant rejection<br />
Category: Immunosupressant; Monoclonal antibody<br />
Half-life: N/A<br />
Clinically important, potentially hazardous interactions<br />
with: corticosteroids, cyclosporine, hemophilus B vaccine,<br />
methylprednisolone, mycophenolate, prednisolone<br />
Reactions<br />
Other<br />
Application-site reactions<br />
Hypersensitivity<br />
Infections<br />
(2004): Huang XS+, Di Yi Jun Yi Da Xue Xue Bao 24(2), 126<br />
DACTINOMYCIN<br />
Synonyms: ACT; actinomycin D<br />
Trade names: Ac-De; Cosmegen (Merck); Cosmegen Lyovac;<br />
Lyovac<br />
Indications: Melanomas, sarcomas<br />
Category: Antibiotic, anthracycline<br />
Half-life: 36 hours<br />
Clinically important, potentially hazardous interactions<br />
with: aldesleukin<br />
Reactions<br />
Skin<br />
Acne (>10%)<br />
(1993): Blatt J+, Med Pediatr Oncol 21, 373<br />
(1983): Bronner AK+, JAmAcadDermatol9, 645<br />
(1982): Dunagin WG, Semin Oncol 9, 14<br />
Actinic keratoses<br />
(1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192<br />
Bullous pemphigoid<br />
(1982): Amer MH+, Int J Dermatol 21, 32<br />
Cellulitis<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
Dermatitis<br />
Erythema<br />
(1997): Coppes MJ+, Med Pediatr Oncol 29, 226<br />
Erythema multiforme<br />
Exanthems<br />
Folliculitis<br />
(1981): Henkes J+, Actas Dermosifiliogr (Spanish) 72, 469<br />
Keratoses (reactivation of)<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
Lichenoid eruption<br />
(2006): Ridola V+, Pediatr Dermatol 23(5), 503<br />
Photo-recall (>10%)<br />
(1997): Coppes MJ+, Med Pediatr Oncol 29, 226<br />
Pigmentation<br />
(2000): Marcoux D+, JAmAcadDermatol43, 540 (with<br />
vincristine)<br />
(1995): Kanwar VS+, Med Pediatr Oncol 24, 329<br />
Pruritus<br />
(2006): Ridola V+, Pediatr Dermatol 23(5), 503<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
Pustules<br />
(1983): Bronner AK+, JAmAcadDermatol9, 645<br />
Toxic epidermal necrolysis<br />
Urticaria<br />
Mucosal<br />
Cheilitis<br />
Oral lesions<br />
(1983): Bronner AK+, JAmAcadDermatol9, 645 (>5%)<br />
Stomatitis (ulcerative) (>5%)<br />
Hair<br />
Hair – alopecia (>10%)<br />
Other<br />
Anaphylactoid reactions/Anaphylaxis (10%)<br />
(1997): Coppes MJ+, Med Pediatr Oncol 29, 226<br />
Injection-site necrosis (>10%)<br />
(1987): Dufresne RG, Cutis 39, 197<br />
Injection-site phlebitis (>10%)<br />
Myalgia/Myositis/Myopathy/Myotoxicity<br />
Phlebitis<br />
(1989): Kerker BJ+, Semin Dermatol 8, 173<br />
DALTEPARIN<br />
Trade names: Fragmin (Pfizer); Fragmine<br />
Indications: Prophylaxis of deep vein thrombosis<br />
Category: Heparin, low molecular weight<br />
Half-life: 4–8 hours<br />
Clinically important, potentially hazardous interactions<br />
with: butabarbital, danaparoid<br />
Reactions<br />
Skin<br />
Allergic reactions (sic) (1–10%)<br />
(2003): Myers B+, Blood Coagul Fibrinolysis 14(5), 485<br />
(1999): Ensom MH+, Pharmacotherapy 19(9), 1013<br />
(1993): Phillips JK+, Br J Haematol 84(2), 349<br />
Bullous dermatitis (1–10%)<br />
(1999): Tong, M, Kota Kinabalu, Malaysia (from Internet)<br />
(observation)<br />
Exanthems (
Change language